問卷

TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Division of Thoracic Medicine

Division of Urology

Division of Others-

Division of Obstetrics & Gynecology

National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Division of Thoracic Medicine

National Cheng Kung University Hospital Dou-Liou Branch (在職)

Division of Hematology & Oncology

Division of Hematology & Oncology

Division of General Internal Medicine

更新時間:2023-09-19

蘇五洲Su, Wu-Chou
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 10 個月

篩選

List

383Cases

2023-09-01 - 2029-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Recruiting13Sites

2023-10-05 - 2029-04-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2019-04-01 - 2025-12-31

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting8Sites

Terminated2Sites

2018-12-01 - 2024-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting3Sites

Terminated4Sites

2018-11-02 - 2028-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2024-05-15 - 2032-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting3Sites

Recruiting3Sites

2022-02-01 - 2029-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2015-11-23 - 2022-04-01

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2018-02-05 - 2022-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated9Sites

馮思中
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2020-08-21 - 2024-03-26

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting2Sites

Terminated5Sites